Antibody data
- Antibody Data
- Antigen structure
- References [6]
- Comments [0]
- Validations [0]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 25887-1-AP - Provider product page
- Provider
- Proteintech Group
- Product name
- Chk1 antibody
- Antibody type
- Polyclonal
- Description
- Chk1 antibody (Cat. #25887-1-AP) is a rabbit polyclonal antibody that shows reactivity with human and has been validated for the following applications: FC, IF, IHC, IP, WB, ELISA.
- Reactivity
- Human
- Host
- Rabbit
- Conjugate
- Unconjugated
- Isotype
- IgG
- Vial size
- 20ul, 150ul
Submitted references Induction of Mitosis Delay and Apoptosis by CDDO-TFEA in Glioblastoma Multiforme.
The HDAC and PI3K dual inhibitor CUDC-907 synergistically enhances the antileukemic activity of venetoclax in preclinical models of acute myeloid leukemia.
MAP4K1 functions as a tumor promotor and drug mediator for AML via modulation of DNA damage/repair system and MAPK pathway.
UBE2T-regulated H2AX monoubiquitination induces hepatocellular carcinoma radioresistance by facilitating CHK1 activation.
A novel alkylating deacetylase inhibitor molecule EDO-S101 in combination with cytarabine synergistically enhances apoptosis of acute myeloid leukemia cells.
RNF126 as a Biomarker of a Poor Prognosis in Invasive Breast Cancer and CHEK1 Inhibitor Efficacy in Breast Cancer Cells.
Tsai TH, Lieu AS, Huang TY, Kwan AL, Lin CL, Hsu YC
Frontiers in pharmacology 2021;12:756228
Frontiers in pharmacology 2021;12:756228
The HDAC and PI3K dual inhibitor CUDC-907 synergistically enhances the antileukemic activity of venetoclax in preclinical models of acute myeloid leukemia.
Li X, Su Y, Hege K, Madlambayan G, Edwards H, Knight T, Polin L, Kushner J, Dzinic SH, White K, Yang J, Miller R, Wang G, Zhao L, Wang Y, Lin H, Taub JW, Ge Y
Haematologica 2021 May 1;106(5):1262-1277
Haematologica 2021 May 1;106(5):1262-1277
MAP4K1 functions as a tumor promotor and drug mediator for AML via modulation of DNA damage/repair system and MAPK pathway.
Ling Q, Li F, Zhang X, Mao S, Lin X, Pan J, Ye W, Wei W, Qian Y, Hu C, Huang X, Wang J, Wang H, Huang J, Wang Y, Jin J
EBioMedicine 2021 Jul;69:103441
EBioMedicine 2021 Jul;69:103441
UBE2T-regulated H2AX monoubiquitination induces hepatocellular carcinoma radioresistance by facilitating CHK1 activation.
Sun J, Zhu Z, Li W, Shen M, Cao C, Sun Q, Guo Z, Liu L, Wu D
Journal of experimental & clinical cancer research : CR 2020 Oct 21;39(1):222
Journal of experimental & clinical cancer research : CR 2020 Oct 21;39(1):222
A novel alkylating deacetylase inhibitor molecule EDO-S101 in combination with cytarabine synergistically enhances apoptosis of acute myeloid leukemia cells.
Jin J, Mao S, Li F, Li X, Huang X, Yu M, Guo W, Jin J
Medical oncology (Northwood, London, England) 2019 Aug 1;36(9):77
Medical oncology (Northwood, London, England) 2019 Aug 1;36(9):77
RNF126 as a Biomarker of a Poor Prognosis in Invasive Breast Cancer and CHEK1 Inhibitor Efficacy in Breast Cancer Cells.
Yang X, Pan Y, Qiu Z, Du Z, Zhang Y, Fa P, Gorityala S, Ma S, Li S, Chen C, Wang H, Xu Y, Yan C, Ruth K, Ma Z, Zhang J
Clinical cancer research : an official journal of the American Association for Cancer Research 2018 Apr 1;24(7):1629-1643
Clinical cancer research : an official journal of the American Association for Cancer Research 2018 Apr 1;24(7):1629-1643
No comments: Submit comment
No validations: Submit validation data